- Presentation - Ionis Pharmaceuticals, Inc.
In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries
- Ionis poised for continued momentum in 2024 with product launches and . . .
About Ionis Pharmaceuticals, Inc For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care Ionis currently has five marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises
- Ionis announces positive results from Phase 2 study of ION224, an . . .
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing
- Ionis announces positive olezarsen topline results from Phase 3 study . . .
About Ionis Pharmaceuticals, Inc For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises
- Investors Media | Ionis Pharmaceuticals, Inc.
Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing
- TAKEAWAY - Ionis Pharmaceuticals, Inc.
TAKEAWAY In the context of the current and other studies targeting apoC-III, olezarsen may treat the continuum of elevated TG levels, including familial and multifactorial chylomicronemia syndrome, severe hypertriglyceridemia, and mild hypertriglyceridemia
- Ionis expands partnership with Sobi to include olezarsen . . .
Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing
- First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 . . .
Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing
|